PT2185155T - Composições farmacêuticas que contêm ligantes recetores de dopamina e métodos de tratamento com a utilização de ligantes recetores de dopamina - Google Patents

Composições farmacêuticas que contêm ligantes recetores de dopamina e métodos de tratamento com a utilização de ligantes recetores de dopamina

Info

Publication number
PT2185155T
PT2185155T PT87826020T PT08782602T PT2185155T PT 2185155 T PT2185155 T PT 2185155T PT 87826020 T PT87826020 T PT 87826020T PT 08782602 T PT08782602 T PT 08782602T PT 2185155 T PT2185155 T PT 2185155T
Authority
PT
Portugal
Prior art keywords
ligands
dopamine
recptor
treatment
methods
Prior art date
Application number
PT87826020T
Other languages
English (en)
Portuguese (pt)
Inventor
Adham Nika
Samoriski Gary
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PT2185155T publication Critical patent/PT2185155T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT87826020T 2007-08-03 2008-08-04 Composições farmacêuticas que contêm ligantes recetores de dopamina e métodos de tratamento com a utilização de ligantes recetores de dopamina PT2185155T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95369407P 2007-08-03 2007-08-03

Publications (1)

Publication Number Publication Date
PT2185155T true PT2185155T (pt) 2018-01-04

Family

ID=40338740

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87826020T PT2185155T (pt) 2007-08-03 2008-08-04 Composições farmacêuticas que contêm ligantes recetores de dopamina e métodos de tratamento com a utilização de ligantes recetores de dopamina

Country Status (20)

Country Link
US (3) US20090036468A1 (enExample)
EP (1) EP2185155B1 (enExample)
JP (1) JP5460594B2 (enExample)
KR (1) KR101612563B1 (enExample)
CN (1) CN101815519B (enExample)
AU (1) AU2008283989B2 (enExample)
CA (1) CA2695519A1 (enExample)
CY (1) CY1119828T1 (enExample)
DK (1) DK2185155T3 (enExample)
EA (1) EA018064B1 (enExample)
ES (1) ES2653852T3 (enExample)
HR (1) HRP20171908T1 (enExample)
HU (1) HUE036004T2 (enExample)
LT (1) LT2185155T (enExample)
MY (1) MY157192A (enExample)
NO (1) NO2185155T3 (enExample)
PL (1) PL2185155T3 (enExample)
PT (1) PT2185155T (enExample)
SI (1) SI2185155T1 (enExample)
WO (1) WO2009020897A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2317852T1 (sl) 2008-07-16 2015-04-30 Richter Gedeon Nyrt. Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
JP5860457B2 (ja) 2010-06-18 2016-02-16 アルトス・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｔｏｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｌｌｃ Ｄ２アンタゴニスト、その合成方法および使用方法
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) * 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
WO2020212951A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
EP4422629A4 (en) * 2021-10-28 2025-09-03 Richter Gedeon Nyrt TREATMENT OF MAJOR DEPRESSIVE DISORDER
JP2025500844A (ja) * 2021-12-13 2025-01-15 コンパス パスファインダー リミテッド 治療抵抗性うつ病の治療に使用するためのサイロシビン及び補助的セロトニン再取り込み阻害剤
CA3244202A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6556540B1 (en) * 1998-05-29 2003-04-29 Paradyne Corporation System and method for non-intrusive measurement of service quality in a communications network
SK287140B6 (sk) * 1999-10-25 2010-01-07 H. Lundbeck A/S Spôsob prípravy citalopramu a medziprodukt na jeho výrobu
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
US20040198809A1 (en) * 2001-05-01 2004-10-07 Connie Sanchez Use of enantiomeric pure escitalopram
WO2003086393A1 (en) * 2002-04-12 2003-10-23 Sepracor, Inc. 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods of use thereof
DE60312874T2 (de) * 2002-06-20 2008-01-17 H. Lundbeck A/S Kombinationstherapie mit verwendung eines serotonin-wiederaufnahmehemmers
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EA200600531A1 (ru) * 2003-09-04 2006-08-25 Х. Лундбекк А/С Сочетание ингибитора обратного захвата серотонина и локсапина
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása

Also Published As

Publication number Publication date
PL2185155T3 (pl) 2018-03-30
CN101815519B (zh) 2013-08-21
US20110015208A1 (en) 2011-01-20
AU2008283989A1 (en) 2009-02-12
US20120028991A1 (en) 2012-02-02
KR20100059830A (ko) 2010-06-04
CA2695519A1 (en) 2009-02-12
EP2185155A1 (en) 2010-05-19
KR101612563B1 (ko) 2016-04-14
HK1144784A1 (en) 2011-03-11
HUE036004T2 (hu) 2018-06-28
MY157192A (en) 2016-05-13
CN101815519A (zh) 2010-08-25
NO2185155T3 (enExample) 2018-03-03
SI2185155T1 (en) 2018-02-28
EA018064B1 (ru) 2013-05-30
ES2653852T3 (es) 2018-02-09
US20090036468A1 (en) 2009-02-05
JP5460594B2 (ja) 2014-04-02
HRP20171908T1 (hr) 2018-01-26
LT2185155T (lt) 2017-12-11
WO2009020897A1 (en) 2009-02-12
EP2185155A4 (en) 2012-04-25
EA201000280A1 (ru) 2010-08-30
EP2185155B1 (en) 2017-10-04
DK2185155T3 (en) 2018-01-02
CY1119828T1 (el) 2018-06-27
JP2010535790A (ja) 2010-11-25
AU2008283989B2 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
PL2185155T3 (pl) Kompozycje farmaceutyczne zawierające ligandy receptora dopaminy i sposoby leczenia z zastosowaniem ligandów receptora dopaminy
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
AP2975A (en) Pharmaceutical formulations containing dopamine receptor ligands
EP2291157A4 (en) COMPOSITIONS AND METHODS FOR TRANSDERING DELIVERY OF PHARMACEUTICAL COMPOUNDS
ZA201008952B (en) Compositions and methods of use for therapeutic antibodies
EP2328934A4 (en) T cell Receptor Antibodies and Method of Use
EP2265731A4 (en) METHODS AND COMPOSITION FOR EVALUATING MEDICATION RESPONSE
EP2205218A4 (en) ESOMEPRAZOLE-CONTAINING PHARMACEUTICAL COMPOSITION
EP2257543A4 (en) MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, PROCESSING METHODS AND PREPARATION METHODS THEREOF
AP3000A (en) Slow release pharmaceutical composition made of microparticles
ZA201005530B (en) Composition for site-specific delivery of imatinib and methods of use
EP2262795A4 (en) MUSCARIN RECEPTOR AGONISTS, COMPOSITIONS, TREATMENT METHODS ASSOCIATED THEREOF AND METHOD FOR THE PRODUCTION THEREOF
IL198634A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
IL196031A0 (en) Polymorph of esomeprazole and process for its preparation
SI1905775T1 (sl) Teraciklične spojine, postopek za njihovo pripravo, farmacevtski sestavki, ki jih vsebujejo, in njihova uporaba kot ligandi dopaminskih receptorjev
GB0814245D0 (en) Medicinal use of receptor ligands
GB0710682D0 (en) Medicinal use of receptor ligands
HU0600832D0 (en) Silicon composition for vertebroplastical use and process for its preparation